Rathbones Group PLC Trims Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Rathbones Group PLC cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,920 shares of the medical equipment provider’s stock after selling 870 shares during the period. Rathbones Group PLC’s holdings in Zimmer Biomet were worth $1,999,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $25,000. Kentucky Trust Co bought a new position in shares of Zimmer Biomet in the fourth quarter worth approximately $39,000. OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth $40,000. SRS Capital Advisors Inc. raised its position in shares of Zimmer Biomet by 146.9% during the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 285 shares during the period. Finally, Atala Financial Inc purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 2.0 %

Shares of ZBH opened at $102.73 on Wednesday. The stock’s 50 day moving average is $106.80 and its two-hundred day moving average is $107.16. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $129.50. The firm has a market cap of $20.45 billion, a P/E ratio of 23.08, a PEG ratio of 1.95 and a beta of 0.84. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the company posted $2.20 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $124.15.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.95% of the stock is owned by insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.